We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$287M
AUM Growth
+$36M
Cap. Flow
+$39.2M
Cap. Flow %
13.67%
Top 10 Hldgs %
59.07%
Holding
34
New
3
Increased
15
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$22.4M
2
CYTK icon
Cytokinetics
CYTK
+$16.5M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$14.6M
4
MGNX icon
MacroGenics
MGNX
+$10.2M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$3.59M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.6M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.55M
3
RLMD icon
Relmada Therapeutics
RLMD
+$5.69M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.29M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.08%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$730M
$29.3M 10.21%
1,668,987
+640,903
+62% +$14.6M
STSA
2
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$21.8M 7.61%
3,096,729
+665,024
+27% +$3.59M
CELC icon
3
Celcuity
CELC
$4.03B
$20.9M 7.28%
+870,967
New +$22.4M
CCCC icon
4
C4 Therapeutics
CCCC
$376M
$18.2M 6.34%
481,094
– –
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$15.4M 5.36%
3,529,465
+545,952
+18% +$2.42M
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$14.9M 5.19%
440,869
+72,421
+20% +$1.85M
CYTK icon
7
Cytokinetics
CYTK
$11B
$13.9M 4.86%
+704,317
New +$16.5M
KURA icon
8
Kura Oncology
KURA
$922M
$13M 4.51%
621,493
+99,938
+19% +$2.48M
COGT icon
9
Cogent Biosciences
COGT
$6.79B
$11.1M 3.86%
1,367,582
+98,387
+8% +$831K
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11M 3.84%
1,748,241
+19,200
+1% +$124K
CLDX icon
11
Celldex Therapeutics
CLDX
$2.77B
$10.8M 3.77%
323,437
-46,514
-13% -$1.28M
MGNX icon
12
MacroGenics
MGNX
$235M
$10.6M 3.69%
393,850
+347,220
+745% +$10.2M
VTGN icon
13
VistaGen Therapeutics
VTGN
$9.29M
$10.5M 3.66%
111,044
-13,279
-11% -$984K
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.75B
$9.45M 3.29%
210,600
-139,000
-40% -$4.59M
EPIX
15
DELISTED
ESSA Pharma
EPIX
$8.05M 2.81%
281,911
+105,090
+59% +$3.05M
KRON
16
DELISTED
Kronos Bio
KRON
$7.16M 2.49%
298,839
– –
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
$6.86M 2.39%
2,929,447
+57,823
+2% +$139K
MREO
18
Mereo BioPharma
MREO
$45.9M
$6.53M 2.27%
2,059,729
+10,972
+0.5% +$36.8K
DYN icon
19
Dyne Therapeutics
DYN
$4.04B
$6.42M 2.24%
305,125
-124,987
-29% -$2.35M
XENE icon
20
Xenon Pharmaceuticals
XENE
$6.32B
$6.08M 2.12%
326,336
+24,944
+8% +$460K
MRSN
21
DELISTED
Mersana Therapeutics
MRSN
$5.83M 2.03%
17,169
– –
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$5.43M 1.89%
226,671
+12,204
+6% +$319K
PMVP icon
23
PMV Pharmaceuticals
PMVP
$66.1M
$4.27M 1.49%
125,000
– –
IVA
24
Inventiva
IVA
$1.05B
$3.58M 1.25%
262,658
– –
MCRB icon
25
Seres Therapeutics
MCRB
$48M
$3.47M 1.21%
7,273
+208
+3% +$87.8K
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Commodore Capital held 34 positions worth $287M, up 14% from $251M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Commodore Capital deployed $39.2M of net new capital in Q2 2021, opening 3 new positions and adding to 15 existing holdings. Its largest new stake was Celcuity: 870,967 shares worth $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $4.59M trimmed.

  • Commodore Capital's largest Q2 2021 buy was Celcuity: 870,967 shares worth $20.9M.
  • Commodore Capital added most to Aclaris Therapeutics in Q2 2021, an estimated $14.6M increase.
  • Commodore Capital's biggest Q2 2021 reduction was Protagonist Therapeutics, cutting an estimated $4.59M.
  • Commodore Capital fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $13.6M.
  • Commodore Capital's ten largest holdings make up 59% of its $287M portfolio in Q2 2021.
  • Commodore Capital opened 3 new positions and closed 5 in Q2 2021.
  • Commodore Capital's portfolio value rose 14% quarter-over-quarter to $287M.

Based on Commodore Capital's 13F filing for Q2 2021, filed 16 Aug 2021.